Gilead says Emvistegrast met primary endpoint in Phase 2 SWIFT dose-ranging study

Gilead announced Emvistegrast 200 mg met its primary endpoint in the Phase 2 SWIFT dose-ranging study, with significant differences across multiple secondary measures of disease activity based on nominal p-values. The company plans to initiate a Phase 3 Emvistegrast monotherapy study in 2027.

Detected & updated continuously · Source: Nebula